Trials / Completed
CompletedNCT03082885
The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF
A Randomized Controlled Trial to Evaluate Efficacy and Safety of Thymosin-α1 Administration in Patients With HBV-related Acute-on-chronic Liver Failure
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A randomized controlled trial to evaluate efficacy and safety of Thymosin-α1 administration in patients with HBV-related Acute-on-chronic liver failure.
Detailed description
Hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) is a severe disease with high mortality. In this study, the investigators intend to assess the efficacy and safety of Thymosin-α1 in patients with HBV-related Acute-on-chronic liver failure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Thymosin-α1 | 1.6 mg s.c injection once per day for 7 days, then 1.6 mg s.c injection twice a week for 11 weeks. |
Timeline
- Start date
- 2017-04-10
- Primary completion
- 2019-06-02
- Completion
- 2019-07-30
- First posted
- 2017-03-17
- Last updated
- 2021-08-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03082885. Inclusion in this directory is not an endorsement.